- Home
- SYRS vs AWH Comparison
SYRS vs AWH Comparison
Compare SYRS & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRS
- AWH
- Stock Information
- Founded
- SYRS 2011
- AWH 1993
- Country
- SYRS United States
- AWH United States
- Employees
- SYRS N/A
- AWH N/A
- Industry
- SYRS Biotechnology: Pharmaceutical Preparations
- AWH Medical/Dental Instruments
- Sector
- SYRS Health Care
- AWH Health Care
- Exchange
- SYRS Nasdaq
- AWH Nasdaq
- Market Cap
- SYRS 5.7M
- AWH 6.2M
- IPO Year
- SYRS 2016
- AWH N/A
- Fundamental
- Price
- SYRS $0.17
- AWH $0.22
- Analyst Decision
- SYRS Hold
- AWH Buy
- Analyst Count
- SYRS 5
- AWH 2
- Target Price
- SYRS $3.00
- AWH $4.40
- AVG Volume (30 Days)
- SYRS 1.2M
- AWH 306.0K
- Earning Date
- SYRS 03-26-2025
- AWH 03-27-2025
- Dividend Yield
- SYRS N/A
- AWH N/A
- EPS Growth
- SYRS N/A
- AWH N/A
- EPS
- SYRS N/A
- AWH N/A
- Revenue
- SYRS $386,000.00
- AWH $8,963,000.00
- Revenue This Year
- SYRS N/A
- AWH $11.87
- Revenue Next Year
- SYRS N/A
- AWH $79.10
- P/E Ratio
- SYRS N/A
- AWH N/A
- Revenue Growth
- SYRS N/A
- AWH N/A
- 52 Week Low
- SYRS $0.16
- AWH $0.21
- 52 Week High
- SYRS $7.96
- AWH $4.43
- Technical
- Relative Strength Index (RSI)
- SYRS 38.78
- AWH 21.26
- Support Level
- SYRS $0.16
- AWH $0.21
- Resistance Level
- SYRS $0.20
- AWH $0.36
- Average True Range (ATR)
- SYRS 0.02
- AWH 0.06
- MACD
- SYRS 0.01
- AWH -0.00
- Stochastic Oscillator
- SYRS 35.75
- AWH 4.76
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.